Ustekinumab
Treatment for Ulcerative Colitis
Typical Dosage: IV induction (6 mg/kg), then 90 mg SC every 8 weeks
Effectiveness
75%
Safety Score
65%
Clinical Trials
32
Participants
2K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
IV induction (6 mg/kg), then 90 mg SC every 8 weeks
Time to Effect
8-12 weeks
Treatment Duration
Long-term
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
75(Treat 75 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$45,000
Monitoring:$2,000
Side Effect Mgmt:$1,000
Total Annual:$48,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$250,000/QALY
QALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$80,000
Cost per Remission
$174,545.45
Comparison vs TNF-alpha inhibitors
Cost Difference
+$20,000/year
More expensive
QALY Difference
+0.15 QALYs
Better outcomes
Dominance
No dominance
Ustekinumab Outcomes
for Ulcerative Colitis
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+60%
Remission Rate
+27.5%
Common Side Effects
Nasopharyngitis
+12%
Headache
+12%
Injection site reactions
+8%
Abdominal pain
+7%
Serious infections
+2.5%
Active Clinical Trials
11 active trials recruiting for Ustekinumab in Ulcerative Colitis
Prediction Model for Response to Biologics and Small Molecular Agent for UC
NCT05186623RECRUITING
300 participants
OBSERVATIONAL
Seoul, South Korea
Started: Feb 5, 2022
Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis
NCT06453317RECRUITINGPHASE2
172 participants
INTERVENTIONAL
Lodz, Poland
Started: Feb 17, 2025
A Direct Head-to-head Comparison of Ustekinumab with Infliximab for the Treatment of Ulcerative Colitis
NCT06786507NOT YET RECRUITING
100 participants
OBSERVATIONAL
Cairo, Egypt
Started: May 15, 2025
A Long-term Extension Study of Ustekinumab in Pediatric Participants
NCT05092269RECRUITINGPHASE3
151 participants
INTERVENTIONAL
Atlanta, United States +46 more
Started: Oct 18, 2021
The PODIUM Study - a Three-arm Comparison of Target Therapies After Anti-TNFα in Ulcerative Colitis
NCT06691061RECRUITING
450 participants
OBSERVATIONAL
Mialn, Italy
Started: Aug 1, 2023
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
NCT04372108RECRUITING
1.06K participants
OBSERVATIONAL
Portsmouth, United States
Started: Jun 24, 2021
Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population
NCT07177209NOT YET RECRUITING
4K participants
OBSERVATIONAL
Walton Oaks, United Kingdom
Started: Dec 30, 2025
De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis
NCT07303686RECRUITINGPHASE4
115 participants
INTERVENTIONAL
Montreal, Canada
Started: Oct 8, 2025
LFMT vs Placebo in New Biologic Start for Ulcerative Colitis
NCT05327790RECRUITINGPHASE2
40 participants
INTERVENTIONAL
Edmonton, Canada
Started: Jun 3, 2022
Risankizumab for Fibrostenotic Crohn's Disease Treatment
NCT07177118NOT YET RECRUITINGPHASE3
260 participants
INTERVENTIONAL
Started: Oct 20, 2025
A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants
NCT06126835ACTIVE NOT RECRUITING
2.83K participants
OBSERVATIONAL
Eden Prairie, United States
Started: Aug 26, 2024
Completed Clinical Trials
8 completed trials for Ustekinumab in Ulcerative Colitis
The Application of Transcriptomics in the Treatment of Ulcerative Colitis With Ustekinumab
NCT05896943COMPLETED
38 participants
OBSERVATIONAL
Athens, Greece
Started: Apr 1, 2022
A Study of Symptom Improvement of Ulcerative Colitis After an Induction Dose of Ustekinumab in Japanese Clinical Practice
NCT04963725COMPLETED
137 participants
OBSERVATIONAL
Bunkyō City, Japan +22 more
Started: Jul 18, 2021
Retrospective Observational Comparison Study Between Ustekinumab and Tofacitinib as Third Line Therapy in a Multicenter Cohort of Patients With Refractory Ulcerative Colitis.
NCT05728008COMPLETED
100 participants
OBSERVATIONAL
Milan, Italy
Started: Apr 5, 2022
Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
NCT03606499COMPLETED
111 participants
OBSERVATIONAL
Vandœuvre-lès-Nancy, France
Started: Sep 26, 2018
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT04630028COMPLETEDPHASE3
112 participants
INTERVENTIONAL
Wilmington, United States +57 more
Started: Mar 17, 2021
Prognosis in UC After First Biological
NCT05530122COMPLETED
192 participants
OBSERVATIONAL
Started: Jan 1, 2009
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT02407236COMPLETEDPHASE3
961 participants
INTERVENTIONAL
Birmingham, United States +246 more
Started: Jul 10, 2015
Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis
NCT04505410COMPLETEDPHASE3
32 participants
INTERVENTIONAL
Miami, United States
Started: Sep 18, 2020
Showing 20 of 36 total trials